NCT05448755 - A Study of ELX-02 in Patients With Alport Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions

Alport Syndrome

Interventions

DRUG

ELX-02

ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).

Trial Locations (4)

3051

NOT_YET_RECRUITING

Royal Children's Hospital, Parkville

3168

RECRUITING

Monash Medical Center, Clayton

NW3 2QG

RECRUITING

Royal Free Hospital, London

WC1N 3JH

RECRUITING

Great Ormond Street Hospital, London